MedTrace Logo

A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47

NCT02340208 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2019-03-14

No results posted yet for this study

Summary

The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in patients with non-squamous non-small cell lung cancer when given as a monotherapy.

Conditions

Interventions

DRUG

L-DOS47

A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.

Sponsors & Collaborators

  • Pharm-Olam International

    collaborator INDUSTRY

  • Helix BioPharma Corporation

    lead INDUSTRY

Principal Investigators

  • Dariusz Kowalski, MD, PhD · The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2017-08-01
Completion
2017-12-20

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02340208 on ClinicalTrials.gov